Systimmune, Inc. announced that it will present clinical data from its lead programs at the ASCO Annual Meeting 2023 in Chicago in June.
In today’s job market, health and retirement benefits are vital tools for competing for employees. The latest tool? Fertility benefits.
Are fertility benefits becoming the latest work perk? Read More »
Learn the considerations product leaders must evaluate as they develop solutions to ease clinician burnout and deliver fast ROI.
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its participation in the annual Digestive Disease Week conference being held this year May 6-9 in Chicago, IL.
Mainz Biomed to Participate in Digestive Disease Week 2023 Read More »
Pliant Therapeutics, Inc. announced 24-week data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, dose-ranging, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
The American Urological Association announced that Pfizer Oncology is the recipient of the 2023 Health Science Award for its outstanding support of the educational, scientific and research goals of the AUA and the Urology Care Foundation in urologic cancer.
Astellas Pharma Inc. and Iveric bio, Inc. announced that on April 29, 2023, the Companies have entered into a definitive agreement under which Astellas through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio for US$40.00 per share in cash
Astellas Enters into Definitive Agreement to Acquire Iveric Bio Read More »
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy and cetrelimab monotherapy in patients with Bacillus Calmette-Guérin -unresponsive high-risk non-muscle-invasive bladder cancer, who are ineligible for, or decline, radical cystectomy.
As a next step in focusing on the US market The Board of Directors of Immunovia AB, has decided to appoint Jeff Borcherding, until now President of Immunovia’s US operation, as global CEO.
UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL.
